Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval Posted on 14th September 2018 |
.jpg) |
| Shares of pharmaceutical companies were in focus with the Nifty Pharma index rising over 2 per cent to 10,623.60 levels in the intra-day deals after Sun Pharmaceutical Industries (Sun Pharma) and Lupin USFDA approval for their respective medicines. Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the National Stock Exchange (NSE) after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension. This approval is from Sun Pharma’s Halol facility. "XELPROS is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations. XELPROSTM is developed using SPARC’s proprietary Swollen Micelle Microemulsion (SMM) technology." it said in a BSE filing earlier today. On the other hand, Lupin, too, rose 2 per cent to Rs 978.75 on the NSE after the company on Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia. The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing. At 10:05 am, all the stocks in the Nifty Pharma index were trading higher in the range of 1 per cent to 4 per cent. |
|
|
|
|
Bharti Airtel defers Q2 results till Nov 14 over ambiguity on AGR verdict Posted on 29th October 2019 |
.jpg) |
Bharti Airtel said on Tuesday it has postponed its second-quarter earnings report to mid-November, as the wireless operator sought clarity on the court ruling asking telecom firms to cough up overdue payments to the government.
Shares of the company, which was expected to release its quarterly numbers later in the day, dropped 3.3 per cent in early trade. |
|
|
Rupee slips 8 paise vs US dollar in early trade amid drop in oil prices Posted on 7th October 2019 |
.jpg) |
The rupee on Monday opened eight paise lower at 70.96 against the US dollar amid drop in crude oil prices and rise in Asian equities. The domestic unit on Friday closed almost flat at 70.88 against after the Reserve Bank of India (RBI) in a widely expected move cut key interest rates by 0.25 percentage point. On a weekly basis, the local unit slumped by 32 paise. |
|
|
LIC pips private insurers in first-year premium growth during April-August Posted on 13th September 2019 |
.jpg) |
In the first five months of the current financial year, first-year premiums of life insurance companies grew by 39.84% (year-on-year) at Rs 1.05 lakh crore as compared to Rs 75,588.35 crore in April-August of 2018-19. Life Insurance Corporation of India (LIC) continued to grow at a faster pace compared to private insurance players, shows the data from the Insurance Regulatory and Development Authority of India (Irdai). |
|
|
Apollo Hospitals rules out further stake sale Posted on 13th September 2019 |
.jpg) |
Apollo Hospitals Enterprise (AHEL) has ruled out further dilution of promoters’ stake in the company. The company also said its Rs 1,337-crore stake sale of Apollo Munich Health Insurance with mortgage major HDFC will be concluded by October. Following these stake sales, the promoters’ pledged position will come down from a high of 76% to 54% by October and eventually to 20% by November or December, company sources said here. |
|
|
World trusts India on Kashmir, not us: Pakistan minister Ijaz Ahmed Shah Posted on 13th September 2019 |
.jpg) |
In a major embarrassment for Pakistan and its Prime Minister Imran Khan, the country's Interior Minister Ijaz Ahmed Shah, a retired brigadier, said the international community didn't believe Pakistan's narrative on Kashmir; instead it is India whose version is trusted. |
|
|
|
|
| Be the first person to write a business review for Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval |
|
|
|